Lucid Diagnostics (NASDAQ:LUCD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) released its earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.06), Zacks reports. The firm had revenue of $1.20 million during the quarter, compared to analysts' expectations of $1.42 million.

Lucid Diagnostics Stock Performance

Shares of Lucid Diagnostics stock traded down $0.06 during midday trading on Friday, hitting $1.54. 332,257 shares of the company traded hands, compared to its average volume of 363,475. The firm's fifty day moving average price is $1.26 and its 200-day moving average price is $1.00. The stock has a market cap of $91.09 million, a price-to-earnings ratio of -1.35 and a beta of 1.34. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.63.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LUCD. Ascendiant Capital Markets cut their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating for the company in a research report on Monday, December 9th. BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a report on Tuesday. Needham & Company LLC increased their price target on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $2.00 price objective on shares of Lucid Diagnostics in a research report on Wednesday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $3.40.

Remove Ads

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.